Therapeutic Effect of Tegafur Combined with Oxaliplatin on Patients with Middle-Advanced Gastric Carcinoma
Objective To explore the clinical effect of tegafur combined with oxaliplatin in the treatment of patients with middle-advanced gastric carcinoma(GC).Methods A total of 65 patients with middle-advanced GC admitted to our hospital from August 2019 to August 2020 were selected and divided into group A(32 cases)and group B(33 cases)according to different treatment methods.Group A was treated with tegafur combined with oxaliplatin,and group B was treated with capecitabine combined with oxaliplatin.The clinical efficacy,gastrin(GAS)and survivin antibody levels,and toxic side effects were compared between the two groups.Results The total effective rate of treatment in group A was 68.75％,higher than 42.42％in group B(P＜0.05).After 4 cycles of treatment,the levels of serum GAS and survivin antibody in group A were lower than those in group B(P＜0.05).No significant difference was found in the incidences of nausea and vomiting,alopecia,liver and kidney injury,and leukopenia between group A and group B(P＞0.05).Conclusions Tegafur combined with oxaliplatin in the treatment of patients with middle-advanced GC has exact effect,which can obviously reduce the serum GAS and survivin antibody levels of patients,and does not significantly increase the occurrence risk of toxic side effects.
国家科技期刊平台
NSTL
万方数据
